These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 16141798)
1. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
3. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients. Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493 [TBL] [Abstract][Full Text] [Related]
4. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161 [TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920 [TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment. Baroudi O; Baroudi T; Omrane I; Moussa A; Mezlini A; Ayari H; Guermazi S; Bahloul A; Bouzaienne H; Uhrhammer N; Bignon YJ; El-Gaaied AB; Bougatef K Med Oncol; 2014 Feb; 31(2):825. PubMed ID: 24415354 [TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy. Su X; Li S; Zhang H; Xiao H; Chen C; Wang G Chin Clin Oncol; 2019 Jun; 8(3):28. PubMed ID: 30823845 [TBL] [Abstract][Full Text] [Related]
8. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Iacopetta B; Grieu F; Joseph D; Elsaleh H Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832 [TBL] [Abstract][Full Text] [Related]
9. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121 [TBL] [Abstract][Full Text] [Related]
10. Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients. Adleff V; Hitre E; Köves I; Orosz Z; Hajnal A; Kralovánszky J Int J Cancer; 2004 Mar; 108(6):852-6. PubMed ID: 14712487 [TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C Oncology; 2006; 70(5):366-77. PubMed ID: 17179731 [TBL] [Abstract][Full Text] [Related]
12. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011 [TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. Mauritz R; Giovannetti E; Beumer IJ; Smid K; Van Groeningen CJ; Pinedo HM; Peters GJ Clin Colorectal Cancer; 2009 Jul; 8(3):146-54. PubMed ID: 19632929 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560 [TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Uchida K; Hayashi K; Kawakami K; Schneider S; Yochim JM; Kuramochi H; Takasaki K; Danenberg KD; Danenberg PV Clin Cancer Res; 2004 Jan; 10(2):433-9. PubMed ID: 14760062 [TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R; Cianchi F; Tonelli F; Mazzei T; Mini E; Genuardi M Pharmacol Res; 2011 Sep; 64(3):242-8. PubMed ID: 21536130 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523 [TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Sulzyc-Bielicka V; Bielicki D; Binczak-Kuleta A; Kaczmarczyk M; Pioch W; Machoy-Mokrzynska A; Ciechanowicz A; Gołębiewska M; Drozdzik M Genet Test Mol Biomarkers; 2013 Nov; 17(11):799-806. PubMed ID: 23968134 [TBL] [Abstract][Full Text] [Related]
19. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Huang ZH; Hua D; Li LH Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422 [TBL] [Abstract][Full Text] [Related]
20. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Fernández-Contreras ME; Sánchez-Hernández JJ; Guijarro M; Gisbert JP; Rivas N; García de Paredes ML; Hinojar-Gutiérrez A; Gamallo C Oncol Rep; 2010 May; 23(5):1393-400. PubMed ID: 20372856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]